This summary was created by AI, based on 1 opinions in the last 12 months.
Natera (NTRA-Q) has demonstrated remarkable growth, showcasing a 145% increase in its stock value over the past year. The company's strong position in cancer detection and its innovative approach to monitoring recurrence of the disease have garnered positive attention from experts. Their well-established franchise is likely to continue to thrive as demand for advanced cancer diagnosis and management solutions grows. Experts emphasize the long-term potential of Natera, suggesting that it is not just a short-term performer, but a company poised for continued success in the healthcare sector. These factors contribute to a favorable outlook for investors considering Natera as part of their portfolio.
Natera is a American stock, trading under the symbol NTRA-Q on the NASDAQ (NTRA). It is usually referred to as NASDAQ:NTRA or NTRA-Q
In the last year, 3 stock analysts published opinions about NTRA-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Natera.
Natera was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Natera.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Natera In the last year. It is a trending stock that is worth watching.
On 2025-04-03, Natera (NTRA-Q) stock closed at a price of $138.74.
Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.